GW Pharmaceuticals (NASDAQ:GWPH) Q1 results:
Revenue: $120.6M (+207.7%); Epidiolex U.S. sales: $116.1M (+216.7%).
Net loss: ($8.0M) (+84.0%); loss/share: ($0.02) (+85.7%).
Cash flow ops: ($18.6M) (+68.2%).
Commercial launch of Epidiolex for tuberous sclerosis complex planned for August (FDA action date: July 31).
Recruitment in Phase 3 in Rett syndrome temporarily suspended due to COVID.
Start of new clinical programs delayed until H2.
Source seeking alpha
High short interest 17%
Revenue: $120.6M (+207.7%); Epidiolex U.S. sales: $116.1M (+216.7%).
Net loss: ($8.0M) (+84.0%); loss/share: ($0.02) (+85.7%).
Cash flow ops: ($18.6M) (+68.2%).
Commercial launch of Epidiolex for tuberous sclerosis complex planned for August (FDA action date: July 31).
Recruitment in Phase 3 in Rett syndrome temporarily suspended due to COVID.
Start of new clinical programs delayed until H2.
Source seeking alpha
High short interest 17%